Compugen Ltd (CGEN)

[biocqr]

Cantor Fitzgerald report:
This morning, before the open, Compugen announced an agreement with Pfizer
(NYSE: PFE, NC) for paid access to its Predictive Peptide Discovery Platform
— Discovery on Demand — for three drug targets. Compugen anticipates
delivery of product candidates within a few months and Pfizer has the option to
exercise worldwide exclusive royalty-bearing licenses with milestone
payments.
Recall, Compugen recently entered into a similar collaboration with Bayer
Schering Pharma for an oncology target and splice variants discovered by
Compugen using its Monoclonal Antibody (mAb) Targets Discovery Platform
— one of a portfolio of 10 in silico predictive platforms developed by
Compugen — using a biocomputational approach that has been experimentally
validated.
We think Compugen's predictive platform portfolio can streamline
identification/validation of relevant biomarkers/therapeutic targets — a
paradigm shift in discovery/development programs that can mitigate risk,
condense timelines, and exponentially increase pharmas' output of both
diagnostics and therapeutics.
This rational approach to discovery — predictive biology pioneered by
Compugen — is the source of its therapeutic pipeline of eight product
candidates. We expect Compugen to enter into additional alliances in the next
6-12 months.
We think Compugen's predictive platforms can impart selectivity and speed to
pharma/dx companies — a significant and relevant competitive advantage for
pipeline-starved companies — to condense discovery/development timelines
plus provide a vast store of improved therapeutics and diagnostics. We reiterate
our BUY rating.

https://cantor.bluematrix.com/docs/pdf/0f6ce9f5-401c-483d-8fdc-c4c6068d2111.pdf